Kuros Biosciences AG 2024 AR2
The report highlights Kuros Biosciences' financial and operational achievements in 2024, including a 125% increase in product sales to CHF 75.6 million, driven by the global adoption of its MagnetOs bone graft technology. For the first time, the company achieved a positive adjusted EBITDA of CHF 9.0 million and reached cash flow breakeven on an annualized basis, aided by the strategic decision to discontinue its Fibrin-PTH candidate. Kuros expanded its global footprint into the UK, Australia, New Zealand, and the Middle East, and secured a landmark five-year US distribution agreement with Medtronic. While formal ESG frameworks are in the early stages of development, the company remains committed to embedding sustainable manufacturing and community engagement principles into its operations.
Company: Kuros Biosciences AG
Sector: Professional & technical services
Country: Switzerland
Year: 2024
Type: AR2
Pages: 158
Back to company
Kuros Biosciences AG
Annual Report
The report highlights Kuros Biosciences' financial and operational achievements in 2024, including a 125% increase in product sales to CHF 75.6 million, driven by the global adoption of its MagnetOs bone graft technology. For the first time, the company achieved a positive adjusted EBITDA of CHF 9.0 million and reached cash flow breakeven on an annualized basis, aided by the strategic decision to discontinue its Fibrin-PTH candidate. Kuros expanded its global footprint into the UK, Australia, New Zealand, and the Middle East, and secured a landmark five-year US distribution agreement with Medtronic. While formal ESG frameworks are in the early stages of development, the company remains committed to embedding sustainable manufacturing and community engagement principles into its operations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Mar 1, 2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees